دورية أكاديمية
Use of a non-endoscopic immunocytological device (Cytosponge™) for post chemoradiotherapy surveillance in patients with oesophageal cancer in the UK (CYTOFLOC): A multicentre feasibility study
| العنوان: | Use of a non-endoscopic immunocytological device (Cytosponge™) for post chemoradiotherapy surveillance in patients with oesophageal cancer in the UK (CYTOFLOC): A multicentre feasibility study |
|---|---|
| المؤلفون: | Christopher M. Jones, Heather O'Connor, Maria O'Donovan, Daniel Hayward, Adrienn Blasko, Ruth Harman, Shalini Malhotra, Irene Debiram-Beecham, Bincy Alias, Adam Bailey, Andrew Bateman, Tom D.L. Crosby, Stephen Falk, Simon Gollins, Maria A. Hawkins, Sudarshan Kadri, Stephanie Levy, Ganesh Radhakrishna, Rajarshi Roy, Raj Sripadam, Rebecca C. Fitzgerald, Somnath Mukherjee |
| المصدر: | EClinicalMedicine, Vol 53, Iss , Pp 101664- (2022) |
| بيانات النشر: | Elsevier, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Medicine (General) |
| مصطلحات موضوعية: | Oesophageal Cancer, Chemoradiation, Radiation, Surveillance, Cytosponge, Medicine (General), R5-920 |
| الوصف: | Summary: Background: Effective surveillance strategies are required for patients diagnosed with oesophageal squamous cell carcinoma (OSCC) or adenocarcinoma (OAC) for whom chemoradiotherapy (CRT) is used as a potentially-curative, organ-sparing, alternative to surgery. In this study, we evaluated the safety, acceptability and tolerability of a non-endoscopic immunocytological device (the Cytosponge™) to assess treatment response following CRT. Methods: This multicentre, single-arm feasibility trial took place in 10 tertiary cancer centres in the UK. Patients aged at least 16 years diagnosed with OSCC or OAC, and who were within 4-16 weeks of completing definitive or neo-adjuvant CRT, were included. Participants were required to have a Mellow-Pinkas dysphagia score of 0-2 and be able to swallow tablets. All patients underwent a single Cytosponge™ assessment in addition to standard of care (which included post-treatment endoscopic evaluation with biopsy for patients undergoing definitive CRT; surgery for those who received neo-adjuvant CRT). The primary outcome was the proportion of consented, evaluable patients who successfully underwent Cytosponge™ assessment. Secondary and tertiary outcomes included safety, study consent rate, acceptance rate, the suitability of obtained samples for biomarker analysis, and the comparative efficacy of Cytosponge™ to standard histology (endoscopy and biopsy or post-resection specimen) in assessing for residual disease. The trial is registered with ClinicalTrials.gov, NCT03529669. Findings: Between 18th April 2018 and 16th January 2020, 41 (42.7%; 95% confidence interval (CI) 32.7-53.2) of 96 potentially eligible patients consented to participate. Thirty-nine (95.1%, 95% CI 83.5-99.4) successfully carried out the Cytosponge™ procedure. Of these, 37 (95%) would be prepared to repeat the procedure. There were only two grade 1 adverse events attributed to use of the Cytosponge™. Thirty-five (90%) of the completed Cytosponge™ samples were suitable for biomarker analysis; 29 (83%) of these were concordant with endoscopic biopsies, three (9%) had findings suggestive of residual cancer on Cytosponge™ not found on endoscopic biopsies, and three (9%) had residual cancer on endoscopic biopsies not detected by Cytosponge™. Interpretation: Use of the CytospongeTM is safe, tolerable, and acceptable for the assessment of treatment response following CRT in OAC and OSCC. Further evaluation of Cytosponge™ in this setting is warranted. Funding: Cancer Research UK, National Institute for Health Research, Medical Research Council. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2589-5370 69165424 |
| العلاقة: | http://www.sciencedirect.com/science/article/pii/S2589537022003947Test; https://doaj.org/toc/2589-5370Test |
| DOI: | 10.1016/j.eclinm.2022.101664 |
| الوصول الحر: | https://doaj.org/article/691654243a41434aa0d1850669448664Test |
| رقم الانضمام: | edsdoj.691654243a41434aa0d1850669448664 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 25895370 69165424 |
|---|---|
| DOI: | 10.1016/j.eclinm.2022.101664 |